$2.30
0.2612.75%
Last update: Nov 9, 4:31 PM
BridgeBio Oncology Therapeutics Inc
BBOTNASDAQ
The average analyst price target for BridgeBio Oncology is $21.20, 829.8% above the current price. Of 9 analysts, 9 rate it Buy. Targets range from $13 to $29. The latest change came on Oct 21, 2026, when Morgan Stanley lowered its price target on BridgeBio Oncology from $18 to $13 and kept an Overweight rating.
Price Target Range — 6 Quarters
Analyst Consensus — 9 Analysts
Rating Trend — Last 9 Months
